Phoenixin is negatively associated with anxiety in obese men |
| |
| Institution: | 1. Charité Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charité-Universitätsmedizin Berlin, Berlin, Germany;2. Charité Center for Internal Medicine with Gastroenterology and Nephrology, Department for Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany;1. Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA;2. Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA;3. Phoenix Pharmaceuticals Inc., Burlingame, CA 94010, USA;4. Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan;1. Department of Histology, Medical University of Silesia, ul. Medyków 18, Katowice 40-752, Poland;2. Manchester Immunology Group, University of Manchester, Oxford Road, Manchester M13 9PT, UK;1. Department for Psychosomatic Medicine, Charité-Universitätsmedizin Berlin, Germany;2. Department of Internal Medicine, Helios Clinic, Zerbst, Germany;3. Department of Quantitative Health Sciences, Medical School University of Massachusetts, Worcester, MA, USA;4. Department of Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tübingen, Germany;1. Charité Center for Internal Medicine and Dermatology, Department for Psychosomatic Medicine; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;2. Department of Internal Medicine, Helios Clinic, Zerbst, Germany;3. Department of Quantitative Health Sciences, Medical School University of Massachusetts, Worcester, MA, USA;4. Department of Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tübingen, Tübingen, Germany |
| |
| Abstract: | Phoenixin was recently identified in the rat hypothalamus and initially implicated in reproductive functions. A subsequent study described an anxiolytic effect of the peptide. The aim of the study was to investigate a possible association of circulating phoenixin with anxiety in humans. We therefore enrolled 68 inpatients with a broad spectrum of psychometrically measured anxiety (GAD-7). We investigated men since a menstrual cycle dependency of phoenixin has been assumed. Obese subjects were enrolled since they often report psychological comorbidities. In addition, we also assessed depressiveness (PHQ-9) and perceived stress (PSQ-20). Plasma phoenixin levels were measured using a commercial ELISA. First, we validated the ELISA kit performing a spike-and-recovery experiment showing a variance of 6.7 ± 8.8% compared to the expected concentrations over the whole range of concentrations assessed, while a lower variation of 1.6 ± 0.8% was observed in the linear range of the assay (0.07–2.1 ng/ml). We detected phoenixin in the circulation of obese men at levels of 0.68 ± 0.50 ng/ml. These levels showed a negative association with anxiety scores (r = −0.259, p = 0.043), while no additional associations with other psychometric parameters were observed. In summary, phoenixin is present in the human circulation and negatively associated with anxiety in obese men, a population often to report comorbid anxiety. |
| |
| Keywords: | Emotion Gut-brain axis Psychobiology Psychoneuroendocrine Psychosomatic |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
